Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,303 total articles
Tarsus Pharmaceuticals COO Neervannan Seshadri sold 11,324 shares of company stock between March 17 and March 19, 2026, realizing $772,443. The transactions, disclosed on a Form 4 filing, were carried out to satisfy tax withholding obligations tied to vesting Restricted Stock Units. The company reported robust fourth-quarter and full-year sales dri…
James J. Savina, General Counsel and Corporate Secretary of Travel & Leisure Co. (NYSE:TNL), sold 31,596 shares on March 17, 2026, for $2,223,726. The transaction leaves Savina with 46,980 shares. Separately, Wyndham Hotels & Resorts announced a dividend increase, a CFO appointment and a $650 million senior notes offering. Citizens raised its price…
Bobak R. Azamian, President, CEO and Board Chair of Tarsus Pharmaceuticals, sold 34,603 shares of common stock between March 17 and March 19, 2026, for about $2.36 million to satisfy tax-withholding on vested restricted stock units. Following the transactions Azamian holds 33,421 shares directly and 857,991 indirectly through a living trust. Tarsus…
Tarsus Pharmaceuticals Chief Medical Officer Elizabeth Yeu Lin completed three sales of company stock between March 17 and March 19, 2026, disposing of 1,144 shares for a total of $78,203 to satisfy tax-withholding obligations tied to restricted stock unit vesting. The company recently reported robust fourth-quarter and full-year 2025 product sales…
Telos CORP (NASDAQ:TLS) Executive Vice President and General Counsel Edward Hutchinson Jr. sold 101,623 shares of common stock across March 17 and 18, 2026, generating roughly $408,153 in proceeds. The two transactions reduced his direct holdings to 567,278 shares, with an additional 15,904.64 shares held indirectly through a 401k plan. The insider…
Tarsus Pharmaceuticals Chief Financial Officer and Chief Strategy Officer Jeffrey S Farrow sold 6,430 shares of the company's common stock across three transactions from March 17 to March 19, 2026, raising $439,566. The trades were disclosed on a Form 4 filing and were conducted to cover tax withholding tied to vested Restricted Stock Units under t…
Mara Holdings, Inc. Chief Financial Officer Salman Hassan Khan, acting through the S & N Khan Family Trust, sold 16,000 shares on March 17, 2026, at $9.18 per share, for total proceeds of $146,880. The transaction reduced the trust's indirect holdings to 343,165 shares while Khan continues to directly hold 1,951,284 shares. The sale was carried out…
Kenneth Duda, president and chief technology officer of Arista Networks, sold $4.29 million of company stock on March 17, 2026, across multiple transactions and also exercised options to buy 32,000 shares. The filings show sales by Duda and related trusts at prices near the company’s market price, coming after Arista reported stronger-than-expected…
Thiel Frederick G., Chief Executive Officer of MARA Holdings, Inc. (NASDAQ:MARA), sold 27,505 shares on March 17, 2026, for $252,495 under a Rule 10b5-1 plan adopted May 28, 2025. The transaction leaves him with 4,788,954 shares. The sale occurs against a backdrop of a pronounced six-month share decline and a sharp fourth-quarter earnings miss that…
Wei Lin, Chief Medical Officer of Revolution Medicines Inc (RVMD), sold 2,073 shares on March 17, 2026, for $206,222 under a pre-arranged Rule 10b5-1 plan tied to RSU tax obligations. The trade took place as RVMD shares traded near $99.29 following a 156% gain over the prior year. The company reported a Q4 2025 loss that missed estimates and higher…
Astera Labs Chief Executive Officer Mohan Jitendra sold 157,501 shares of the company's common stock on March 17, 2026, under a pre-arranged 10b5-1 trading plan, generating $20,723,773 in proceeds. The transactions were reported on a Form 4 filing with the Securities and Exchange Commission. The disposition occurred in multiple tranches at prices b…
Stephen Michael Kelsey, Revolution Medicines’ President of Research and Development, sold 4,302 shares on March 17, 2026 under a prearranged Rule 10b5-1 plan to meet tax obligations tied to restricted stock unit vesting. The transaction occurred as the stock trades near its 52-week high and after the company reported a fourth-quarter 2025 loss that…
Revolution Medicines President and CEO Mark A. Goldsmith sold 12,871 shares on March 17, 2026, under a pre-set 10b5-1 plan to cover taxes tied to RSU vesting. The transaction amounted to roughly $1.28 million and occurred while the stock traded close to its 52-week high. The company recently reported a wider net loss for Q4 2025 and retains more ca…
Revolution Medicines Chief Operating Officer Margaret A. Horn executed a planned sale of 4,583 common shares on March 17, 2026, generating $455,918. The transaction occurred as RVMD shares trade close to their 52-week high. The company recently reported a wider quarterly loss driven by elevated R&D spending and has drawn multiple analyst reactions …
A consortium including Pale Fire Capital entities and two individuals purchased 1,602,505 shares of Phreesia, Inc. (NASDAQ: PHR) between March 17 and March 19, 2026, for a total of $18.3 million. The transactions increased the group's holdings to 7,648,829 shares. The activity coincides with Phreesia's recent refinancing of its bridge loan, a produ…
Jeff Cislini, general counsel of Revolution Medicines, sold 2,958 shares of the company's common stock in two trades on March 17 and March 19, 2026, receiving about $291,889. The March 17 sale was executed under a 10b5-1 instruction letter adopted in May 2023 to cover tax obligations from restricted stock unit vesting; the March 19 sale followed a …
Xiaolin Wang, Executive Vice President of Clinical Development at Revolution Medicines, sold 2,010 shares on March 17, 2026, generating proceeds of $199,955. The transaction was carried out under a Rule 10b5-1 trading plan put in place November 17, 2025, to cover taxes from restricted stock unit vesting. The move comes while RVMD shares trade close…
Revolution Medicines CFO Jack Anders sold 2,753 shares on March 17, 2026, generating $273,869 in proceeds under a pre-arranged Rule 10b5-1 plan. The move comes as RVMD shares trade close to their 52-week high after a 156% gain year-over-year. The company reported a wider-than-expected Q4 2025 loss driven by higher research and development and SG&A …
Alignment Healthcare Chief Operating Officer Sebastian Burzacchi sold 15,361 shares of common stock on March 18, 2026, in a transaction tied to tax withholding for vested restricted stock units. The shares were disposed at a weighted-average price of $17.84, netting $274,040. The company recently reported strong fourth-quarter growth and faces a pl…
CytomX Therapeutics Chief Medical Officer Yu-Waye Chu sold 21,279 shares on March 17, 2026, raising $136,675 to satisfy tax liabilities tied to vesting restricted stock units. The price per share in the sale was $6.423, a premium to the firm's recent market quote. Separately, CytomX announced a $250 million common stock and pre-funded warrant offer…
Ambarella Inc.'s CFO John Alexander Young sold a total of 7,615 Ordinary Shares in two transactions in March 2026, netting roughly $406,005, while also acquiring shares through the exercise of performance stock units and receipt of vested restricted stock units. The moves coincide with the company's fourth-quarter fiscal 2026 results that slightly …
Ambarella Inc. CEO Feng-Ming Wang completed a series of equity transactions between March 17 and March 19, 2026, resulting in the sale of 27,059 shares for about $1.44 million. The moves included the exercise of Performance Stock Units, tax-covering share sales, and receipt of shares as bonus payment. These insider actions coincide with recent quar…
Ambarella Inc.'s Chief Operations Officer Lee Chan W. disposed of 10,370 ordinary shares in two trades on March 17 and March 19, 2026, generating roughly $552,213. The transactions - executed at prices between $52.77 and $54.14 per share - were performed to satisfy tax obligations stemming from the vesting of restricted stock units. The insider act…
Alignment Healthcare Chief Executive Officer John E. Kao sold 73,046 shares on March 18, 2026, generating roughly $1.3 million to satisfy tax withholding tied to restricted stock unit vesting. The sale was not a discretionary trade. The company reported robust fourth-quarter results with membership and revenue gains, while a 13.2 million-share seco…
Globalstar, Inc. (NASDAQ:GSAT) Chief Executive Officer Paul E. Jacobs reported a sale of $42,525 in company shares on March 19, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The filing shows Jacobs sold 714 shares of Voting Common Stock at prices between $59.56 and $59.5816. On the same date he exercised options to…
